Incase You Missed It: James Greenwood Op-Ed “The Future of Drug Pricing”


Last week, BIO President & CEO, James Greenwood had an op-ed on value-based drug pricing in The Hill

In the article Jim highlights that this approach is about “rewarding value, rather than volume”, and “is showing great promise in other areas of health-care”.

Jim writes that ensuring access to new breakthrough cures and therapies expected in the next couple years will remain a concern for drug-manufacturers, policy makers and the general public.  

He closes by noting that if Congress wants to achieve the full promise of the 21st Century Cures Act, it will have to “think creatively about how the country pays for prescription drugs” and value-based pricing “will need to be at the center of this important effort.” You can read the full op-ed here.

Share This Post:

Comments are closed.